LigoCyte Pharmaceuticals was a vaccine discovery and development company with a first-in-class vaccine for norovirus, a pathogen that is a leading cause of viral gastroenteritis (stomach flu). LigoCyte Pharmaceuticals was acquired by Takeda.
Status: Acquired
Ikano Therapeutics
Ikano Therapeutics is a specialty pharmaceutical company focused on developing Midazolam Nasal Spray (USL261) for acute repetitive seizures. Ikano was acquired by UCB.
FoldRx
FoldRx Pharmaceuticals focuses on creating disease modifying drug therapies for diseases of protein misfolding. FoldRx developed, tafamidis, the first-in-class therapy approved or TTR amyloidosis. FoldRx was acquired by Pfizer.
Dimension Therapeutics
Dimension Therapeutics was a leader in the development of AAV (adeno-associated virus) gene therapies for rare disease. Dimension Therapeutics was acquired by Ultragenyx Pharmaceuticals (NASDAQ: RARE).
CardioKine
CardioKine is a pharmaceutical company focused on the development of lixivaptan, an oral compound under development for the potential treatment of hyponatremia in patients with congestive heart failure. CardioKine was acquired by Cornerstone Therapeutics.
Bikam Pharmaceuticals
Bikam Pharmaceuticals is a drug discovery company focused on developing novel therapies for diseases of the eye with exceptionally high unmet medical need. Bikam Pharmaceuticals was acquired by Shire.
Acacia Pharma
Acacia Pharma (EURONEXT: ACPH) is a commercially driven hospital pharmaceutical group focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. Acacia developed BARHEMSYS to marketing approval and was acquired by Eagle Pharmaceuticals in 2022.